Trial Profile

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NB 001 (Primary)
Indications Herpes labialis
Focus Registrational; Therapeutic Use
Acronyms SHaRCS
Sponsors BlueWillow Biologics

Most Recent Events

07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
16 Jan 2012 Actual patient number (847) added as reported by ClinicalTrials.gov.
16 Jan 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com